Form 8-K - Current report:
SEC Accession No. 0001564590-22-003250
Filing Date
2022-02-01
Accepted
2022-02-01 08:04:04
Documents
12
Period of Report
2022-02-01
Items
Item 8.01: Other Events

Document Format Files

Seq Description Document Type Size
1 8-K trvi-8k_20220201.htm   iXBRL 8-K 41000
  Complete submission text file 0001564590-22-003250.txt   174926

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA trvi-20220201.xsd EX-101.SCH 5729
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE trvi-20220201_lab.xml EX-101.LAB 20175
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE trvi-20220201_pre.xml EX-101.PRE 12063
6 EXTRACTED XBRL INSTANCE DOCUMENT trvi-8k_20220201_htm.xml XML 3687
Mailing Address 195 CHURCH STREET 14TH FLOOR NEW HAVEN CT 06510
Business Address 195 CHURCH STREET 14TH FLOOR NEW HAVEN CT 06510 203-304-2499
Trevi Therapeutics, Inc. (Filer) CIK: 0001563880 (see all company filings)

EIN.: 450834299 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38886 | Film No.: 22576928
SIC: 2834 Pharmaceutical Preparations